Hereditary angioedema with F12 mutation: Clinical features and enzyme polymorphisms in 9 Southwestern Spanish families

Ann Allergy Asthma Immunol. 2016 Nov;117(5):520-526. doi: 10.1016/j.anai.2016.09.001. Epub 2016 Oct 24.

Abstract

Background: Information on F12 mutation hereditary angioedema (HAE) is still limited, but Spain is now recognized as having one of the highest concentrations of cases in Western Europe.

Objective: To describe unique features of HAE in Spanish carriers of the F12 mutation and investigate a potential role for angiotensin-converting enzyme (ACE) and aminopeptidase-P polymorphisms in disease expression.

Methods: This was a prospective observational cohort study of 35 individuals (80% females) from 9 unrelated families carrying the p.Thr309Lys mutation. We analyzed detailed medical records and complement activity (C4, C1q, C1 inhibitor) and screened for mutations in exon 9 of the F12 gene and 2 polymorphisms: XPNPEP2 c-2399A and the ACE insertion/deletion polymorphism.

Results: The p.Thr309Lys mutation was found in all individuals. Three of the 9 index patients had a clinically negative family history, and 72% of males and 29% of females were asymptomatic. Sixteen females (44% estrogen dependent, 56% estrogen sensitive) were clearly symptomatic. The most common locations of attacks were the abdomen (63%), face (25%), and peripheral structures (6%). Triggers other than hyperestrogenic states included stress and minor trauma or pressure. Short-term treatment with C1-inhibitor concentrate and icatibant and long-term prophylaxis with tranexamic acid were useful. The combination of the I allele and A allele was detected in 17% of patients.

Conclusion: The polymorphisms analyzed were not a major determinant of disease expression in our population. We recommend searching for F12 mutations in women with edema attacks without associated wheals and with normal C1-inhibitor levels, particularly when they develop symptoms during hyperestrogenic states or are of Western European or African origin.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Adult
  • Aminopeptidases / genetics*
  • Angioedemas, Hereditary / drug therapy
  • Angioedemas, Hereditary / genetics*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antifibrinolytic Agents / therapeutic use
  • Bradykinin / analogs & derivatives
  • Bradykinin / therapeutic use
  • Complement C1 Inhibitor Protein / therapeutic use
  • Complement Inactivating Agents / therapeutic use
  • Factor XII / genetics*
  • Female
  • Humans
  • Male
  • Mutation
  • Peptidyl-Dipeptidase A / genetics*
  • Polymorphism, Genetic
  • Prospective Studies
  • Spain
  • Tranexamic Acid / therapeutic use
  • White People / genetics
  • Young Adult

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antifibrinolytic Agents
  • Complement C1 Inhibitor Protein
  • Complement Inactivating Agents
  • Tranexamic Acid
  • icatibant
  • Factor XII
  • Aminopeptidases
  • X-Pro aminopeptidase
  • ACE protein, human
  • Peptidyl-Dipeptidase A
  • Bradykinin